De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Monash IVF Group Beheer

Beheer criteriumcontroles 3/4

De CEO Monash IVF Group's is Michael Knaap, benoemd in Oct2018, heeft een ambtstermijn van 5.5 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 1.21M, bestaande uit 49.8% salaris en 50.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.23% van de aandelen van het bedrijf, ter waarde A$ 1.11M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 9.2 jaar.

Belangrijke informatie

Michael Knaap

Algemeen directeur

AU$1.2m

Totale compensatie

Percentage CEO-salaris	49.8%
Dienstverband CEO	6yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	5.3yrs
Gemiddelde ambtstermijn bestuur	9.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Michael Knaap's beloning veranderd ten opzichte van Monash IVF Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$1m	AU$601k	-AU$7m
Mar 31 2024	n/a	n/a	AU$9m
Dec 31 2023	n/a	n/a	AU$24m
Sep 30 2023	n/a	n/a	AU$23m
Jun 30 2023	AU$1m	AU$567k	AU$22m
Mar 31 2023	n/a	n/a	AU$19m
Dec 31 2022	n/a	n/a	AU$17m
Sep 30 2022	n/a	n/a	AU$18m
Jun 30 2022	AU$794k	AU$552k	AU$18m
Mar 31 2022	n/a	n/a	AU$21m
Dec 31 2021	n/a	n/a	AU$23m
Sep 30 2021	n/a	n/a	AU$24m
Jun 30 2021	AU$908k	AU$501k	AU$25m
Mar 31 2021	n/a	n/a	AU$22m
Dec 31 2020	n/a	n/a	AU$18m
Sep 30 2020	n/a	n/a	AU$15m
Jun 30 2020	AU$561k	AU$479k	AU$12m
Mar 31 2020	n/a	n/a	AU$15m
Dec 31 2019	n/a	n/a	AU$18m
Sep 30 2019	n/a	n/a	AU$19m
Jun 30 2019	AU$520k	AU$402k	AU$20m
Mar 31 2019	n/a	n/a	AU$19m
Dec 31 2018	n/a	n/a	AU$19m
Sep 30 2018	n/a	n/a	AU$20m
Jun 30 2018	AU$424k	AU$350k	AU$21m

Compensatie versus markt: De totale vergoeding ($USD 833.34K ) Michael } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 899.18K ).

Compensatie versus inkomsten: De vergoeding van Michael is gestegen terwijl het bedrijf verliesgevend is.

CEO

Michael Knaap

6yrs

Tenure

AU$1,207,516

Compensatie

Mr. Michael D. Knaap serves as Chief Executive Officer, Managing Director and Executive Director of Monash IVF Group Limited since April 15, 2019. Mr. Knaap served as an Interim Chief Executive Officer of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Knaap	CEO, MD & Executive Director	6yrs	AU$1.21m	0.23% A$ 1.1m
Malik Jainudeen	Group CFO & Company Secretary	5.5yrs	AU$583.85k	0.0049% A$ 23.6k
Hamish Hamilton	Chief Operating Officer	4.6yrs	AU$608.35k	0.041% A$ 197.6k
Richard Henshaw	Executive Director	10.5yrs	AU$393.90k	0.35% A$ 1.7m
Deirdre Zander-Fox	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Thierry Panthier	Chief Information Officer	2.8yrs	geen gegevens	geen gegevens
Fiona Allen	Chief Marketing Officer	5.3yrs	geen gegevens	geen gegevens
Peggy North	Chief People & Culture Officer	no data	geen gegevens	geen gegevens
Tedd Fuell	Chief Governance & Risk Officer	no data	geen gegevens	geen gegevens
Johannes Lagerwij	Managing Director of Asia	1.8yrs	geen gegevens	geen gegevens

5.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van MVF is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Knaap	CEO, MD & Executive Director	5.5yrs	AU$1.21m	0.23% A$ 1.1m
Richard Henshaw	Executive Director	10.5yrs	AU$393.90k	0.35% A$ 1.7m
Neil Broekhuizen	Independent Non-Executive Director	10.3yrs	AU$107.65k	0.090% A$ 428.8k
Josef Czyzewski	Independent Non-Executive Director	10.3yrs	AU$126.38k	0.059% A$ 283.4k
Richard Davis	Independent Non-Executive Chairman	10.3yrs	AU$183.69k	0.047% A$ 223.0k
Zita Peach	Independent Non-Executive Director	8yrs	AU$117.03k	0.024% A$ 113.7k
Catherine West	Independent Non-Executive Director	4.1yrs	AU$107.65k	0.0095% A$ 45.4k
Catherine Aston	Independent Non-Executive Director	less than a year	AU$35.88k	0.020% A$ 94.3k

9.2yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MVF wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.2 jaar).

Monash IVF Group Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Monash IVF Group Limited Announces Board Changes

Independent Non-Executive Director recently bought AU$93k worth of stock

Monash IVF Group Limited Appoints Cathy Aston as an Independent Non-Executive Director and A Member of the Audit and Risk Management Committee Effective from 26 February 2024

Insufficient new directors

Monash IVF Group Limited, Annual General Meeting, Nov 11, 2022

Insufficient new directors

Recent updates

Monash IVF Group Limited Announces Board Changes

Independent Non-Executive Director recently bought AU$93k worth of stock

Monash IVF Group Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on October 11, 2024

Full year 2024 earnings released: AU$0.017 loss per share (vs AU$0.056 profit in FY 2023)

Monash IVF Group Limited (ASX:MVF)completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd.

Upcoming dividend of AU$0.025 per share

First half 2024 earnings released: EPS: AU$0.033 (vs AU$0.027 in 1H 2023)

Monash IVF Group Limited Appoints Cathy Aston as an Independent Non-Executive Director and A Member of the Audit and Risk Management Committee Effective from 26 February 2024

First half dividend of AU$0.025 announced

Monash IVF Group Limited to Report First Half, 2024 Results on Feb 23, 2024

Upcoming dividend of AU$0.022 per share at 3.5% yield

Monash IVF Group Limited Announces Fully Franked Final Dividend for Fiscal Year Ended June 30, 2023, Payable on 11 October 2023

Full year 2023 earnings released: EPS: AU$0.056 (vs AU$0.047 in FY 2022)

Monash IVF Group Limited Provides Update on Class Action Lawsuit

Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre.

Upcoming dividend of AU$0.022 per share at 4.2% yield

First half 2023 earnings released: EPS: AU$0.027 (vs AU$0.031 in 1H 2022)

Monash IVF Group Limited to Report First Half, 2023 Results on Feb 21, 2023

Insufficient new directors

Monash IVF Group Limited (ASX:MVF) completed the acquisition of ART Associates Queensland #2 Pty Ltd.

Upcoming dividend of AU$0.022 per share

Full year 2022 earnings released: EPS: AU$0.047 (vs AU$0.065 in FY 2021)

Monash IVF Group Limited Announces Ordinary Fully Paid Distribution for the Six Months Ended June 30, 2022, Payable on October 7, 2022

Monash IVF Group Limited to Report Fiscal Year 2022 Results on Aug 26, 2022

Monash IVF Group Limited, Annual General Meeting, Nov 11, 2022

Insufficient new directors

Monash IVF Group Limited (ASX:MVF) agreed to acquire PIVET Medical Centre for AUD 9.4 million.

Insufficient new directors

Monash IVF Group Limited Announces Fully Franked Distribution for the Six Months That Ended December 31, 2021, Payable on April 4, 2022

Monash IVF Group Limited to Report First Half, 2022 Results on Feb 17, 2022

Monash IVF Group Limited Updates Temporary Suspension of IVF Procedures Lifted in Victoria

Upcoming dividend of AU$0.021 per share

Full year 2021 earnings released: EPS AU$0.065 (vs AU$0.046 in FY 2020)

Independent Non-Executive Director recently bought AU$192k worth of stock

New 90-day low: AU$0.70

Revenue beats expectations

First half 2021 earnings released: EPS AU$0.037 (vs AU$0.035 in 1H 2020)

New 90-day high: AU$0.80

New 90-day high: AU$0.72

New 90-day high: AU$0.65

Monash IVF Group Limited Provides Earnings Guidance for the Second Half and Full Year of the Fiscal Year 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd